UNSPSC 51171936: Disuprazole

This classification denotes a proton pump inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V81J4OO2OT. European Medicines Agency schedules Disuprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06327MIG. Disuprazole generally arises in the molecular formula C16H17N3OS2.

UNSPSC 51171936 Disuprazole is a Commodity code with minimal relevance to recent state and local procurement activity. The code nominally identifies a specific pharmaceutical active ingredient, but the recent opportunities posted under this classification do not procure disuprazole itself; instead, they solicit broad drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals across multiple therapeutic categories. The scope mismatch suggests either tagging error in the source system or that disuprazole represents a minor component within larger pharmacy or testing service contracts that state and local buyers classify under this code without material purchasing focus on the ingredient itself. Issuing bodies include county corrections departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state jurisdictions. The actual work being solicited encompasses offender drug testing (specimen collection, immunoassay screening, and confirmation testing), pharmacy benefit program design, and generic pharmaceutical supply agreements rather than disuprazole acquisition or testing.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with a July 23, 2026 response deadline and an estimated contract value of $600,000 over two years with optional renewals, requesting approximately 25,031 annual tests across five- and six-panel screens with LC/MS/MS or GC/MS confirmation. The Texas Health and Human Services Commission posted an exploratory Request for Information on March 27, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with an April 3, 2026 response window. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, distributing across multiple states including Oregon. These opportunities reflect state and local demand for drug testing operations, pharmacy program innovation, and pharmaceutical supply agreements, but show limited actual procurement of disuprazole as a discrete product line.